CLINUVEL completes enrolment in world-first stroke study
CLINUVEL today announced that it has completed enrolment in its world-first study...
Read More
CLINUVEL’S GROWTH AND EXPANSION - H.C. Wainwright Bioconnect Conference 2022
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the H.C. Wainwright...
Read More
Progress of CLINUVEL’s DNA Repair Program
CLINUVEL PHARMACEUTICALS LTD today announced that two xeroderma pigmentosum (XP) patients have...
Read More
Chair's Letter to Shareholders
On behalf of the Board, thank you to those shareholders who chose...
Read More
CLINUVEL Kommuniqué VI
Der letzte Monat war eine tragische Lektion in Bezug auf die Herausforderungen...
Read More
SCENESSE® as Vitiligo Monotherapy
CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) will be evaluated as a monotherapy in...
Read More
Vitiligo Communiqué IV
CLINUVEL’s fourth Vitiligo Communiqué discusses the long-term consequences, both physical and psychological,...
Read More
CLINUVEL Kommuniqué V
CLINUVELs fünftes Nachrichtenkommuniqué für 2021. Bespricht EPP, klinisches Programm, IR-Update und mehr.
Read More
CLINUVEL Communiqué V
CLINUVEL’s fifth News Communiqué for 2021. Discusses EPP, clinical program, IR update...
Read More
CLINUVEL’S GROWTH AND EXPANSION - Jefferies London Healthcare Conference
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the 2021 Jefferies...
Read More
Results of Annual General Meeting 2021
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read More
CEO's Address - 2021 Annual General Meeting
2021 CLINUVEL Annual General Meeting address from CEO, Dr Philippe Wolgen
Read More
CLINUVEL Expands Pharmaceutical Portfolio
Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders
Read More